# Legend Biotech Corporation American (LEGN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $21.52, market value $4.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Legend Biotech Corporation American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **Price / book: 3.4×**. The shares trade at 3.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.9%** (5-yr avg -1.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 56.6%**. Legend Biotech Corporation American keeps 56.6% of revenue after the direct cost of what it sells.
- **Operating margin: -4.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -28.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -29.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -56.0%**. Return on all capital, debt included, is -56.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -5.3%**. Each dollar of assets produces -5.3% of profit.

## Growth
- **Revenue growth (1 yr): 64.0%** (3-yr 106.4%/yr, 5-yr 68.8%/yr). Revenue grew 64.0% over the last year, against 68.8% a year compounded over five years.
- **EPS growth (1 yr): -68.8%**. Earnings per share fell 68.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Interest coverage: -2.5×**. Operating profit covers interest only -2.5×: fragile.
- **Altman Z-score: 4.58**. A Z-score of 4.58 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Legend Biotech Corporation American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (15 analysts). 15 analysts cover Legend Biotech Corporation American; the consensus is buy, with an average price target of $49.25 (+129% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -38.5%** (YTD -1.0%, 3-mo -34.0%). The shares are down 38.5% over twelve months including dividends.
- **From 52-week high: -42.6%** (32.5% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.44** (volatility 74%). Beta of 0.44 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LEGN · Page: https://foliofundamentals.com/stocks/legn

Not investment advice.